Form 4: MAIA Biotechnology Director Stan Smith Acquires 100,000 Shares and Warrants

Director Stan Smith purchased 100,000 shares of MAIA Biotechnology and related warrants on November 1, 2024, increasing his indirect holdings.

Summary

• On November 1, 2024, Stan Smith, a director of MAIA Biotechnology, acquired 100,000 shares of common stock at a price of $2.51 per share.
• The purchase was made pursuant to a Securities Purchase Agreement and issued under the Issuer's 2021 Equity Incentive Plan.
• Smith also acquired warrants to purchase 100,000 shares of common stock at an exercise price of $2.259.
• These warrants were also purchased pursuant to a Securities Purchase Agreement and are deemed options issued under the Issuer's 2021 Equity Incentive Plan.
• The warrants become exercisable six months after the issuance date (May 1, 2025) and expire five years after the initial exercise date (May 1, 2030).
• Following the transaction, Smith indirectly owns 957,568 shares through The Stan V. Smith Trust Dated 1993.
• Smith also indirectly owns 100,000 warrants through The Stan V. Smith Trust Dated 1993.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's purchase of shares and warrants, indicating confidence. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by a director is generally viewed positively.

Stakeholder Impact

• The purchase could positively influence shareholder sentiment.

Key Dates